Similarly, Liu et al. [42] conducted a meta-analysis to evaluate the risk of malignant neoplasia after GLP-1 receptor agonist administration and reported no increase in the risk of malignant neoplasia among individuals with type 2 diabetes who received GLP-1 receptor agonist administration. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.